
    
      An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of
      Aldoxorubicin (INNO-206) Plus Doxorubicin HCl Administered as Infusions Every 3 Weeks in
      Subjects with Advanced Solid Tumors
    
  